Trial Profile
Exploratory Clinical Trial Using BR55 Targeted Ultrasound Contrast Agent in the Detection of Prostate Cancer by Molecular Imaging of VEGFR2
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs BR-55 (Primary)
- Indications Prostate cancer
- Focus Diagnostic use
- Sponsors Bracco Diagnostics
- 18 Apr 2018 New trial record